MAGE-A10 Gene Expression in Stomach Cancer
Author Information
Author(s): Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K, Tajiri T
Primary Institution: Tama-Nagayama Hospital, Nippon Medical School
Hypothesis
The study aims to assess the significance of MAGE-A protein and MAGE-A10 gene expressions in the progression of stomach cancer and to elucidate suitable patients for active immunotherapy using MAGE-A10 peptide.
Conclusion
MAGE-A10 gene expression is significantly higher in patients with liver metastasis and is associated with reduced survival duration.
Supporting Evidence
- MAGE-A protein expression was detected in 65.9% of patients with liver metastasis.
- MAGE-A10 mRNA expression was found in 80.5% of patients with liver metastasis.
- Patients with MAGE-A10 gene expression had a significantly shorter survival duration.
- The concordance rate between MAGE-A protein and MAGE-A10 mRNA expression was 81.7%.
- Patients with liver metastasis had a 5-year survival rate of only 6%.
Takeaway
This study found that a specific gene related to stomach cancer, MAGE-A10, is more active in patients with liver metastasis, which could help doctors choose better treatments.
Methodology
Tumour samples from 71 patients were analyzed for MAGE-A protein expression using immunohistochemistry and MAGE-A10 mRNA expression using in situ hybridization.
Potential Biases
Potential bias due to the selection of patients from a single institution.
Limitations
The study had a small sample size and focused only on patients from a single hospital.
Participant Demographics
Patients included 41 with liver metastasis and 30 without, with a median age of 70 years.
Statistical Information
P-Value
P=0.0003, P<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website